BiotechTube

ACE-083

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Facioscapulohumeral Muscular Dystrophy

Conditions

Facioscapulohumeral Muscular Dystrophy, Charcot-Marie-Tooth Disease

Trial Timeline

May 10, 2019 → Mar 11, 2020

NCT ID
NCT03943290

About ACE-083

ACE-083 is a phase 2 stage product being developed by Merck for Facioscapulohumeral Muscular Dystrophy. The current trial status is terminated. This product is registered under clinical trial identifier NCT03943290. Target conditions include Facioscapulohumeral Muscular Dystrophy, Charcot-Marie-Tooth Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT03943290Phase 2Terminated
NCT02257489Phase 1Completed

Competing Products

12 competing products in Facioscapulohumeral Muscular Dystrophy

See all competitors
ProductCompanyStageHype Score
ACE-083 + ACE-083 or placeboMerckPhase 2
52
Placebo + RO7204239RochePhase 2
52
AOC-1020 + PlaceboAvidity BiosciencesPhase 3
74
Apitegromab + PlaceboScholar Rock HoldingPhase 2
49
Losmapimod oral tablet + Placebo oral tabletFulcrum TherapeuticsPhase 2
44
Losmapimod + Placebo oral tabletFulcrum TherapeuticsPhase 3
69
LosmapimodFulcrum TherapeuticsPhase 2
44
LosmapimodFulcrum TherapeuticsPhase 2
44
ATYR1940aTyr PharmaPhase 1/2
33
ATYR1940aTyr PharmaPhase 1/2
33
Placebo + ATYR1940aTyr PharmaPhase 1/2
33
ATYR1940aTyr PharmaPhase 1/2
33

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85